To explore the impact of these mutations, CRISPR/Cas9 has been utilized to create ERα-positive breast cancer models where the wild-type ERα gene is replaced with the mutated forms ERαY537S or ERαD538G, allowing researchers to study resistance mechanisms and develop new therapeutic strategies. The gene discussed is ESR1; the disease is breast cancer.